Automated breast ultrasound one step closer to FDA approval

Editorial Staff | | Health Imaging | Diagnostic Imaging
U-Systems has received a pre-market approvable (PMA) letter from the FDA for its somo•v Automated Breast Ultrasound (ABUS) system for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue. 

Using technology to automate the ultrasound imaging process, the U-Systems’ somo•v ABUS system was developed for the high-volume, breast cancer screening environment. The somo•VIEWer Advanced 3D Workstation enables review and archive of patient exams.

Final approval of the company’s PMA application for the system remains subject to satisfactory review and inspection of U-Systems manufacturing facilities, methods and controls. The company said it plans to work with the FDA to complete this final inspection.

 

Editorial Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.